New antibody drug conjugate enters first human trial for advanced cancers

NCT ID NCT05948826

Ongoing Disease control Sponsor: TORL Biotherapeutics, LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called TORL-3-600 in 70 people with advanced solid tumors or colorectal cancer. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find the best dose, and see if it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TORL-3-600 (antibody drug conjugate)
What this could lead to: If successful, this could lead to a new treatment option for advanced cancers that have not responded to other therapies.
What could go wrong: This is an early, first-in-human trial with only 70 participants, so safety and effectiveness are not yet known. Side effects may occur, and the drug may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR COLORECTAL CANCER

Contacts and locations

Locations

Fort Wayne Medical Oncology and Hematology Inc.

Fort Wayne, Indiana, 46845, United States
Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
McGill University Health Centre

Montreal, Quebec, H4A 3J1, Canada
Providence Medical Foundation

Fullerton, California, 92835, United States
Sarah Cannon Research Institute

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute-Tennessee

Nashville, Tennessee, 37203, United States
UCLA - JCCC Clinical Research Unit

Los Angeles, California, 90095, United States
University Health Network, Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Washington University School of Medicine-Siteman Cancer Center

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.